<p>The Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD tool for common mental health disorders administered by health care professionals. This examination addresses 12 different mental health disorders.</p>
<p>The PHQ-9 is a diagnostic tool that is specific to depression. The PHQ contains modules on 12 different mental health disorders including mood, anxiety, and some of the sleep disorder modules. This tool assesses the 15 most common physical symptoms in primary care. A shorter, alternative version of the PHQ, called the Brief PHQ, assesses depression, anxiety, psychological stressors, and women's reproductive health. This scale simply scores each of the 9 Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria based on the mood module from the original PRIME-MD.</p>
<p>Developed by Drs. R.L. Spitzer, J.B.W. Williams, K. Kroenke and colleagues, with an educational grant from Pfizer, Inc. No permission required to reproduce, translate, display or distribute.</p>
Registration Status:
Qualified
Designations:
Designation:
Patient Health Questionnaire-9 (PHQ-9)
Tags:
Health
Designations:
Definition:
<p>The Patient Health Questionnaire (PHQ) is a self-administered version of the PRIME-MD tool for common mental health disorders administered by health care professionals. This examination addresses 12 different mental health disorders.</p>
<p>The PHQ-9 is a diagnostic tool that is specific to depression. The PHQ contains modules on 12 different mental health disorders including mood, anxiety, and some of the sleep disorder modules. This tool assesses the 15 most common physical symptoms in primary care. A shorter, alternative version of the PHQ, called the Brief PHQ, assesses depression, anxiety, psychological stressors, and women's reproductive health. This scale simply scores each of the 9 Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria based on the mood module from the original PRIME-MD.</p>
<p>Developed by Drs. R.L. Spitzer, J.B.W. Williams, K. Kroenke and colleagues, with an educational grant from Pfizer, Inc. No permission required to reproduce, translate, display or distribute.</p>
Tags:
Health
Reference Documents:
ID:
PatientHealthQuestionnaire-9_2014Mar19.pdf
Title:
NIDA Clinical Trials Network - Patient Health Questionnaire-9 (PHQ-9)
Monitoring depression treatment outcomes with the patient health questionnaire-9. (Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K.)
URI:
http://www.ncbi.nlm.nih.gov/pubmed/15550799
Provider Org:
Department of General Internal and Psychosomatic Medicine, Heidelberg University Medical Center, D-69120 Heidelberg, Germany. bernd.loewe@med.uni-heidelberg.de
Language Code:
US
Document:
BACKGROUND: Although effective treatment of depressed patients requires regular follow-up contacts and symptom monitoring, an efficient method for assessing treatment outcome is lacking. We investigated responsiveness to treatment, reproducibility, and minimal clinically important difference of the Patient Health Questionnaire-9 (PHQ-9), a standard instrument for diagnosing depression in primary care.
METHODS:
This study included 434 intervention subjects from the IMPACT study, a multisite treatment trial of late-life depression (63% female, mean age 71 years). Changes in PHQ-9 scores over the course of time were evaluated with respect to change scores of the SCL-20 depression scale as well as 2 independent structured diagnostic interviews for depression during a 6-month period. Test-retest reliability and minimal clinically important difference were assessed in 2 subgroups of patients who completed the PHQ-9 twice exactly 7 days apart.
RESULTS:
The PHQ-9 responsiveness as measured by effect size was significantly greater than the SCL-20 at 3 months (-1.3 versus -0.9) and equivalent at 6 months (-1.3 versus -1.2). With respect to structured diagnostic interviews, both the PHQ-9 and the SCL-20 change scores accurately discriminated patients with persistent major depression, partial remission, and full remission. Test-retest reliability of the PHQ-9 was excellent, and its minimal clinically important difference for individual change, estimated as 2 standard errors of measurement, was 5 points on the 0 to 27 point PHQ-9 scale.
CONCLUSIONS:
Well-validated as a diagnostic measure, the PHQ-9 has now proven to be a responsive and reliable measure of depression treatment outcomes. Its responsiveness to treatment coupled with its brevity makes the PHQ-9 an attractive tool for gauging response to treatment in individual patient care as well as in clinical research.